Abstract
several drugs to treat neurodegenerative diseases, however, almost none of them could delay progress of these diseases and offer cure. A key molecular pathway implicated in neurodegenerative diseases is the misfolding aggregation and accumulation of proteins in neurons. Chloro-oxime derivatives, such as bimoclomol and arimoclomol, promote the expression of heat shock proteins and improve the abilities of normal protein folding and degrade misfolded proteins. Based on the structure of bimoclomol and arimoclomol, we substituted the pyridine and piperazine by TMP and other amino groups, and synthesised a series of novel chloro-oxime derivatives. Among these chloro-oxime derivatives, compounds 9b and 13b were demonstrated to be neuroprotective against MG-132-induced neurotoxicity in SH-SY5Y cells.
Keywords
References
Nagai Y, Fujikake N, Popiel HA, Wada K. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases. Curr Pharm Biotechnol. 2010;11(2):188–97.
Pehlivan SB. Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases.Pharmaceut Res. 2013;30(10):2499–511.
Fisher A. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer’s disease. J Neurochem. 2012;120(Suppl 1):22–33.
Poon LH, Kang GA, Lee AJ. Role of tetrabenazine for Huntington’s disease-associated chorea. Ann Pharmacother. 2010;44(6):1080–9.
Traynor BJ, Bruijn L, Conwit R, Beal F, O’Neill G, Fagan SC, Cudkowicz ME. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology. 2006;67(1):20–7.
Agorogiannis EI, Agorogiannis GI, Papadimitriou A, Hadjigeorgiou GM. Protein misfolding in neurodegenerative diseases. Neuropathol Appl Neurobiol. 2004;30(3):215–24.
Gavrin LK, Denny RA, Saiah E. Small molecules that target protein misfolding. J Med Chem. 2012;55(24):10823–43.
Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci. 2005;6(1): 11–22.
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature.1997;388(6645):839–40.
Kalmar B, Kieran D, Greensmith L. Molecular chaperones as therapeutic targets in amyotrophic lateral sclerosis. Biochem Soc Trans. 2005;33(Pt 4):551–2.
Soti C, Nagy E, Giricz Z, Vigh L, Csermely P, Ferdinandy P. Heat
shock proteins as emerging therapeutic targets. Br J Pharmacol.
;146(6):769–80.
Westerheide SD, Morimoto RI. Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem. 2005;280(39):33097–100.
Zhang Z, Wei T, Hou J, Li G, Yu S, Xin W. Tetramethylpyrazine scavenges superoxide anion and decreases nitric oxide production in human polymorphonuclear leukocytes. Life Sci. 2003;72(22):2465–72.
Liu X, Zhang R, Xu W, Li C, Zhao Q, Wang X. Synthesis of the novel liqustrazine derivatives and their protective effect on injured vascular endothelial cell damaged by hydrogen peroxide.
Bioorg Med Chem Lett. 2003;13(13):2123–6.
Sun Y, Jiang J, Zhang Z, Yu P, Wang L, Xu C, Liu W, Wang Y. Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke. Bioorg Med Chem. 2008;16(19):8868–74.
Zhou Y, Vu K, Chen Y, Pham J, Brady T, Liu G, et al. Chloro-oxime derivatives as novel small molecule chaperone amplifiers. Bioorg Med Chem Lett. 2009;19(11):3128–35.
Henkel JG, Hane JT, Gianutsos G. Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution. J Med Chem. 1982;25(1):51–6.
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.